This study was designed to determine the effect of antihypertensive agents (calcium channel blockers) on the levels of remnant-like particle (RLP) cholesterol; a major risk factor for coronary heart disease, during treatment of hypertension. Thirty six hypertensive patients of both sexes were selected into this study. Twenty-five of them were treated with amlodipine while eleven patients were treated with cilnidipine all for 3 months. At the beginning and after 3 months of treatment, serum RLP-cholesterol levels were measured in the two treatment groups. RLP-cholesterol level was significantly reduced after clinidipine treatment while the reduction in RLP-cholesterol level after amlodipine treatment was not statistically significant. Our ...
This review describes the clinical profile and rationale for the development of a single-pill formul...
This study was designed to investigate whether the L/N-type calcium channel blocker, cilnidipine, ha...
Background: In many countries, combination therapy with amlodipine and atorvastatin is indicated for...
Objectives. Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective pro...
A reduction in blood pressure (BP) levels is the most important mechanism accounting for the reducti...
Background: Hypertension is a widespread public health problem and a major risk factor. Amlodipine, ...
Therapies that lower blood pressure or lipid levels slow the progression of atherosclerosis, and red...
Background Antihypertensive agents lower the risk of cardiovascular events, but whether they affect ...
In order to determine the safety or otherwise of amlodipine, we evaluated lipid and lipoprotein indi...
Essential hypertension is a major cardiovascular risk factor. Although pharmacological treatment is ...
Objectives: Hypertension is well established as a major risk factor for cardiovascular disease. Alth...
Objective: The present study was aimed to compare the effect of calcium channel blocker (Amlodipine,...
Coronary heart disease (CHD) is a major cause of morbidityand mortality. Recent evidence supports th...
Background: Calcium channel blockers (CCBs) are proposed to play a pivotal role for the management a...
It is generally accepted that hypertension doubles the risk of cardiovascular disease, of which coro...
This review describes the clinical profile and rationale for the development of a single-pill formul...
This study was designed to investigate whether the L/N-type calcium channel blocker, cilnidipine, ha...
Background: In many countries, combination therapy with amlodipine and atorvastatin is indicated for...
Objectives. Cilnidipine, an L-/N-type calcium channel blocker (CCB), has unique organ-protective pro...
A reduction in blood pressure (BP) levels is the most important mechanism accounting for the reducti...
Background: Hypertension is a widespread public health problem and a major risk factor. Amlodipine, ...
Therapies that lower blood pressure or lipid levels slow the progression of atherosclerosis, and red...
Background Antihypertensive agents lower the risk of cardiovascular events, but whether they affect ...
In order to determine the safety or otherwise of amlodipine, we evaluated lipid and lipoprotein indi...
Essential hypertension is a major cardiovascular risk factor. Although pharmacological treatment is ...
Objectives: Hypertension is well established as a major risk factor for cardiovascular disease. Alth...
Objective: The present study was aimed to compare the effect of calcium channel blocker (Amlodipine,...
Coronary heart disease (CHD) is a major cause of morbidityand mortality. Recent evidence supports th...
Background: Calcium channel blockers (CCBs) are proposed to play a pivotal role for the management a...
It is generally accepted that hypertension doubles the risk of cardiovascular disease, of which coro...
This review describes the clinical profile and rationale for the development of a single-pill formul...
This study was designed to investigate whether the L/N-type calcium channel blocker, cilnidipine, ha...
Background: In many countries, combination therapy with amlodipine and atorvastatin is indicated for...